文献速递胸部肿瘤

免疫遗传变异预测PD-1/PD-L1抑制剂的免疫相关不良事件

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors.
PubMed 文献 · Eur J Cancer · 2023-02-23

本研究纳入接受PD-1/PD-L1阻断治疗的实体瘤患者,对18个基因的39个变异进行基因分型,分析其与免疫相关不良事件(irAEs)及无irAEs生存的关联。鉴定出MAPK1 rs3810610、PTPRC rs6428474、ADAD1 rs17388568和IL6 rs1800796四个预测irAEs的免疫遗传变异,并在PD-1阻断或肺癌亚组中呈现相似趋势。

要点

  • MAPK1 rs3810610的C等位基因是全级别irAEs的风险预测因子(OR=1.495)。
  • PTPRC rs6428474的A等位基因对全级别irAEs呈保护作用(OR=0.717)。
  • ADAD1 rs17388568的A等位基因增加高级别irAEs风险(OR=2.599)。

核心结论

  • 首次在PD-1/PD-L1阻断治疗的肿瘤患者中鉴定出与irAEs及无irAEs生存相关的免疫遗传多态性,可能作为潜在的预测生物标志物。

研究设计与样本

  • 研究招募接受PD-1/PD-L1阻断治疗的实体瘤患者并进行随访,通过蛋白质-蛋白质相互作用网络和Cytoscape筛选肿瘤免疫及自身免疫性疾病的关键基因,采用多重基因分型法对18个基因的39个变异进行基因分型,分析遗传变异与irAEs及无irAEs生存的关联。

主要发现

  • MAPK1 rs3810610的C等位基因是全级别irAEs的风险预测因子(OR=1.495,95%CI=1.093-2.044,P=0.012),PTPRC rs6428474的A等位基因是保护因素(OR=0.717,95%CI=0.521-0.987,P=0.041)。
  • ADAD1 rs17388568的A等位基因增加高级别irAEs风险(OR=2.599,95%CI=1.355-4.983,P=0.003),IL6 rs1800796的G等位基因保护患者免于高级别irAEs(OR=0.425,95%CI=0.205-0.881,P=0.018)。
  • 显著的免疫遗传变异在PD-1阻断或肺癌亚组中呈现相似趋势。
  • 多因素Cox回归分析中,MAPK1 rs3810610与全级别无irAEs生存独立相关(CC vs CT或TT:HR=0.71,95%CI=0.52-0.99,P=0.042)。
  • ADAD1 rs17388568(AA vs AG或GG:HR=0.11,95%CI=0.025-0.49,P=0.004)和IL6 rs1800796(GG或GC vs CC:HR=3.10,95%CI=1.315-7.29,P=0.01)是高级别无irAEs生存的独立变量。

临床怎么用

  • 作者认为这些免疫遗传多态性可能作为预测irAEs的潜在生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PD-1/PD-L1 inhibitors have brought remarkable benefits but can cause profound immune-related adverse events (irAEs). The host immunogenetic background is likely to play a role in irAE susceptibility. In this study, we aimed to identify potential immunogenetic biomarkers to predict irAEs. METHODS: Patients with solid tumours receiving PD-1/PD-L1 blockade were recruited and followed up. Genes considered pivotal contributors to tumour-immunity and autoimmune diseases were screened out via protein-protein interaction network and Cytoscape. Consequently, thirty-nine variants in eighteen genes were genotyped using the multiplex genotyping assay. Association analysis between genetic variants and irAEs as well as irAEs-free survival was performed. RESULTS: Four immunogenetic variants as predictive biomarkers of irAEs were identified. The C allele of Mitogen-Activated Protein Kinase 1 (MAPK1) rs3810610 (odds ratio [OR] = 1.495, 95% confidence interval [CI] = 1.093-2.044, P = 0.012) was a risk predictor while the A allele of PTPRC rs6428474 (OR = 0.717, 95% CI = 0.521-0.987, P = 0.041) was a protective factor for all-grade irAEs. The A allele of ADAD1 rs17388568 (OR = 2.599, 95% CI = 1.355-4.983, P = 0.003) increased the risk while the G allele of IL6 rs1800796 (OR = 0.425, 95% CI = 0.205-0.881, P = 0.018) protected patients from high-grade irAEs. Significant immunogenetic variants reached a similar tendency in PD-1 blockade or lung cancer subgroups. In multivariate Cox regression analysis, the MAPK1 rs3810610 was an independent factor regarding all-grade irAEs-free survival (CC versus CT or TT: hazard ratio [HR] = 0.71, 95% CI = 0.52-0.99, P = 0.042). ADAD1 rs17388568 (AA versus AG or GG: HR = 0.11, 95% CI = 0.025-0.49, P = 0.004) and IL6 rs1800796 (GG or GC versus CC: HR = 3.10, 95% CI = 1.315-7.29, P = 0.01) were independent variables for high-grade irAEs-free survival. CONCLUSION: We first identified several immunogenetic polymorphisms associated with irAEs and irAEs-free survival in PD-1/PD-L1 blockade-treated tumour patients, and they may serve as potential predictive biomarkers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Xin Z, You L, Na F, et al. Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors. Eur J Cancer. 2023. PMID: 36917924. doi:10.1016/j.ejca.2023.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。